There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agenus (AGEN – Research Report) and Balchem (BCPC – Research Report) with bullish sentiments.
Agenus (AGEN)
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Agenus, with a price target of $8.00. The company’s shares closed last Friday at $1.60, close to its 52-week low of $1.25.
According to TipRanks.com, Bodnar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Agenus has an analyst consensus of Strong Buy, with a price target consensus of $8.10, which is a 406.3% upside from current levels. In a report issued on May 25, EF Hutton also initiated coverage with a Buy rating on the stock with a $8.30 price target.
See today’s best-performing stocks on TipRanks >>
Balchem (BCPC)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Balchem, with a price target of $150.00. The company’s shares closed last Friday at $132.82.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Balchem with a $150.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AGEN:
- AGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Agenus up 4% after FDA approves GSK’s Arexvy RSV vaccine
- Agenus to present Phase 1, Phase 2 trial data at ASCO meeting
- B. Riley came away ‘encouraged’ on Agenus after AACR
- Agenus receives Fast Track Designation from FDA for botensilimab, balstilimab
